Breaking News

Trials & Filings in Brief: Nov. 18, 2013

By Gil Roth | November 18, 2013

AbbVie, ChanRx, Enanta, Gilead, Merck, Sanofi

Phase II
ChanRx posts positive A-Fib data . . . read more

Phase III
AbbVie, Enanta show HCV results . . . read more

Filings
Gilead gets EC approval for Vitekta . . . read more

Merck's Noxafil IV gets priority review . . . read more

Cancellations
Sanofi ends JAK2 development . . . read more

blog comments powered by Disqus